How to Choose the Right Targets for MMAE-ADC Success?

Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the selectivity of monoclonal antibodies with the potency of cytotoxic payloads. Yet even a highly optimized ADC can struggle if the underlying target is poorly selected. For MMAE-based ADCs, target selection is particularly important because the target influences tumor localization, cellular uptake, intracellular trafficking, payload release, and ultimately the therapeutic window.

MMAE, or monomethyl auristatin E, is a highly potent microtubule-disrupting payload. Its effectiveness depends not only on its cytotoxic activity but also on whether the ADC can deliver sufficient MMAE to tumor cells while limiting exposure to healthy tissues. Therefore, successful MMAE-ADC development starts with a target that is biologically appropriate for both the disease and the payload.

High Tumor Expression Is Only the Beginning

Target abundance can influence how many ADC molecules reach a tumor cell, but high antigen density does not automatically translate into therapeutic success. Antibody affinity, epitope location, antigen accessibility, receptor turnover, internalization kinetics, and intracellular trafficking can all influence effective MMAE delivery.

A target expressed at moderate levels but rapidly internalized may be more useful than a highly abundant antigen that remains primarily on the cell surface. This is especially relevant for MMAE because the payload needs to be released inside the target cell to exert its intracellular mechanism of action. For this reason, target evaluation should move beyond conventional expression profiling. The key question is not only how much target is present, but also what happens after the ADC binds.

Match the Target to MMAE Biology

MMAE is a potent antimitotic agent that disrupts microtubule dynamics and interferes with cell division. This creates an important consideration during target selection: the target should ideally provide access to tumor cell populations that are biologically vulnerable to microtubule inhibition.

Tumors with substantial proliferative activity can be attractive candidates because actively dividing cells have a strong dependence on functional microtubule networks. However, this does not mean that only rapidly proliferating tumors are suitable for MMAE-ADCs. Tumor growth rate, cell-cycle distribution, drug exposure, resistance mechanisms, and intracellular payload sensitivity all need to be considered. A target that efficiently delivers MMAE to a biologically vulnerable tumor population is therefore more compelling than one selected solely because of high expression.

Linker Design Should Be Considered During Target Selection

Target selection, linker selection, and payload selection should not be treated as completely independent decisions. For many MMAE-ADCs, a cleavable linker is central to intracellular payload release. Valine-citrulline-based linkers are widely used in MMAE ADC development because they can support protease-mediated cleavage within intracellular compartments. Enfortumab vedotin and polatuzumab vedotin demonstrate how MMAE can be combined with cleavable linker strategies in clinically validated ADCs.

The important point for early target evaluation is that the target should support the entire delivery pathway: binding, internalization, intracellular trafficking, linker cleavage, payload release, and cytotoxic activity. A target with excellent surface expression but poor trafficking toward compartments where linker processing occurs may ultimately be less attractive than expected.

Target Selection Can Also Improve Safety by Choosing the Right Disease Cell

The ideal ADC target does not always have to be completely absent from normal tissues. A more practical strategy can be to identify a disease-associated cell population in which the target is substantially enriched. This principle is particularly relevant when the target is associated with pathogenic or malignant cell populations. If the target is preferentially expressed on disease-driving cells while showing lower expression on essential healthy cells, targeted delivery may still provide a meaningful therapeutic window. A similar concept applies to cancer. Rather than asking whether a target is absolutely tumor-specific, developers should ask whether its expression pattern creates a clinically manageable therapeutic window.

Look at Clinically Validated Targets—but Do Not Copy Them Blindly

Clinical experience provides valuable evidence for target selection, but successful targets should be treated as biological benchmarks rather than automatic templates. HER2 demonstrates the value of combining substantial tumor expression with effective antibody-mediated delivery. Nectin-4, targeted by enfortumab vedotin, illustrates the potential of an MMAE-based ADC against a tumor-associated surface protein. CD79B provides another example of exploiting lineage-associated antigen expression in malignant B cells.

PSMA has attracted extensive interest because of its selective expression pattern in prostate cancer, while 5T4 has been investigated as a tumor-associated internalizing antigen. Trop-2 is another prominent ADC target whose expression across multiple solid tumors has supported extensive development. These examples reveal an important lesson: there is no universal best ADC target. A target becomes compelling when its expression pattern, internalization behavior, tumor biology, disease setting, and safety profile align with the characteristics of the selected payload.

Avoid Choosing Targets by Expression Alone

One of the most persistent errors in early ADC discovery is ranking targets according to tumor expression and assuming that the highest-ranked candidate will produce the best ADC. High expression may not compensate for poor internalization. Strong internalization may not compensate for problematic normal-tissue expression. A highly tumor-selective antigen may still fail if it is poorly accessible or rapidly recycled instead of degraded. Likewise, a target that looks excellent in a homogeneous cell-line model may behave very differently in a heterogeneous patient-derived tumor. A more reliable development strategy is to progressively filter candidates using expression, accessibility, internalization, trafficking, tumor biology, normal-tissue distribution, and functional ADC response.

Final Considerations for MMAE-ADC Target Selection

The success of an MMAE-ADC rarely depends on a single feature. The most promising targets combine high and accessible tumor expression, limited expression in critical normal tissues, efficient internalization, productive intracellular trafficking, and biological compatibility with MMAE. For heterogeneous solid tumors, the bystander effect of MMAE can provide an additional advantage, while rapidly proliferating tumor populations may be particularly vulnerable to its microtubule-disrupting mechanism. At the same time, linker stability, intracellular cleavage, and normal-tissue expression should be considered from the beginning rather than treated as downstream optimization issues.

Ultimately, the best MMAE-ADC target is not simply the antigen with the highest tumor expression. It is the target that provides a strong tumor-selective delivery opportunity while maintaining a realistic therapeutic window. Evaluating target biology, internalization, tumor heterogeneity, payload compatibility, and safety together can help identify candidates with a stronger rationale for successful MMAE-ADC development.

FQA

MMAE Antibodies

MMAE Antigen

MMAE ELISA